BioCryst Pharmaceuticals BCRX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $173.38M+62.2% | $91.34M-14.1% | $84.08M-13.2% | $88.03M+12.3% | $106.88M+26.7% | ||
| $66.81M-64.8% | $185.01M-14.4% | $128.8M-44.8% | $172.01M-11.2% | $189.9M-24.7% | ||
| $109.27M+17.0% | $106.82M+35.1% | $91.33M+9,033% | $91.18M+4,203% | $93.39M+2,510% | ||
| $28.18M+12.3% | $23.99M+3.5% | $23.39M+8.1% | $22.21M-9.5% | $25.1M-20.0% | ||
| $373.63M-8.9% | $404.35M-4.2% | $355.68M-16.7% | $398.46M+9.6% | $409.98M-8.3% | ||
| $9.37M+23.4% | $8.78M+12.9% | $8.4M+13.1% | $8.46M+10.4% | $7.59M-3.0% | ||
| $465.05M-3.1% | $514.16M+4.8% | $446.42M-9.1% | $457.19M-3.2% | $480.05M+2.6% | ||
| $10.96M+9.0% | $15.83M+35.9% | $5.57M-58.7% | $8.59M+10.3% | $10.05M-15.6% | ||
| —— | —— | —— | —— | —— | ||
| $1.24M-31.2% | $1.31M-28.5% | $1.44M-22.0% | $1.62M— | $1.8M— | ||
| $195.39M+39.7% | $196.07M+22.2% | $190.24M+23.9% | $177.16M+37.3% | $139.86M+16.6% | ||
| $395.2M+25.3% | $0-100% | $194.37M-38.2% | $242.79M-22.6% | $315.41M+2.2% | ||
| $1.02B— | $633.31M— | $834.31M— | $878.78M— | —— | ||
| 450M0.0% | 450M+21,483% | 450M0.0% | 450M0.0% | 450M0.0% | ||
| -$2.23B-25.9% | -$1.51B+14.9% | -$1.75B-0.5% | -$1.76B-2.1% | -$1.77B-3.1% | ||
| -$553.84M-22.6% | -$119.15M+75.0% | -$387.89M+17.2% | -$421.59M+11.4% | -$451.93M+5.1% | ||
| $465.05M-3.1% | $514.16M+4.8% | $446.42M-9.1% | $457.19M-3.2% | $480.05M+2.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are BioCryst Pharmaceuticals's total assets?
- BioCryst Pharmaceuticals (BCRX) holds $465.1M in total assets, down 3.1% year over year.
- How much debt does BioCryst Pharmaceuticals have?
- BioCryst Pharmaceuticals carries $411.8M in total debt against -$553.8M of shareholders' equity, a debt-to-equity ratio of 0.14.
- How much cash does BioCryst Pharmaceuticals have?
- BioCryst Pharmaceuticals holds $173.4M in cash and equivalents.
- Can BioCryst Pharmaceuticals cover its short-term obligations?
- Its current ratio is 1.91 — current assets exceed current liabilities.
- Where does BioCryst Pharmaceuticals's balance sheet data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
